Revenues and EBIT of Danish operations growth by 23% and 89% Delays meant that order intake dropped ...
Bolaget visar god motståndskraft och efterfrågan är bättre än förväntat.
Redeye has opened an Analyst Q&A in conjunction with the latest research update on Smart Eye.
Redeye strengthens its positive view of Vertiseit following a strong Q3 report, with significant imp...
Fortsatt pressat NAV NAV i kvartalet uppgick till 318 kr, vilket motsvarar en nedgång om 55% y/y och...
Stark lönsamhet och tillväxt Omsättningen i kvartalet uppgick till 29,9 mkr, vilket motsvarar en til...
Redeye comments on yesterday’s news regarding RLS’ terminated collaboration agreement with Convatec.
Redeye endorses today’s news that Egetis has outlicensed the rights to Emcitate in Japan to Fujimoto...
Redeye states that reported Q3 numbers were somewhat better than we expected, with sales and earning...
TCECUR (”Koncernen”) levererade en Q3-rapport som överraskade positivt på översta raden, men där mar...
Sales SEK 17.7m, -13% vs. ABGSCe SEK 20.5m EBITDA SEK -1.
Q3 sales -5% vs ABGe, EBITA -36% on weak margins FY guidance unchanged, implying ~25% EBITA gowth in...
Redeye comments on Modelon's Q3 2023 report, which was in line on the ARR side while slightly lower ...
Redeye saw a Q3 report showing sales above our estimates, with a total growth of 47% for the quarter...
Redeye comments on Maximum Entertainment ahead of its Q3-results (due 15 November) where we expect a...
Redeye embraces the strong sales growth in the quarter, and we emphasise the coming revenue growth d...
Group net sales were EUR 31.4m in Q3 (Refinitiv consensus EUR 34m) meanwhile Q3 adjusted EBITDA was ...
Redeye believes that the management is effectively executing on their strategic plan.
Redeye updates on G5 following the company’s Q3-results which came in lower than expected.
Redeye comments on Active Biotech's Q3 report and the rights issue that was simultaneously announced...
